[go: up one dir, main page]

BRPI0909840A2 - Uso de 4-tio-2-deoxinucleosídios - Google Patents

Uso de 4-tio-2-deoxinucleosídios

Info

Publication number
BRPI0909840A2
BRPI0909840A2 BRPI0909840-2A BRPI0909840A BRPI0909840A2 BR PI0909840 A2 BRPI0909840 A2 BR PI0909840A2 BR PI0909840 A BRPI0909840 A BR PI0909840A BR PI0909840 A2 BRPI0909840 A2 BR PI0909840A2
Authority
BR
Brazil
Prior art keywords
deoxynucleosides
thio
Prior art date
Application number
BRPI0909840-2A
Other languages
English (en)
Inventor
John A Secrist Iii
Kamal N Tiwari
Joseph A Maddry
Original Assignee
Southern Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southern Res Inst filed Critical Southern Res Inst
Publication of BRPI0909840A2 publication Critical patent/BRPI0909840A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
BRPI0909840-2A 2008-03-12 2009-03-12 Uso de 4-tio-2-deoxinucleosídios BRPI0909840A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/047,197 US8859589B2 (en) 2008-03-12 2008-03-12 Use of 4′-thio-2′-deoxynucleosides as anti orthopoxvirus agents
PCT/US2009/036869 WO2009114651A2 (en) 2008-03-12 2009-03-12 Use of '-thio-2'-deoxynucleosides as anri orthopoxvirus agents

Publications (1)

Publication Number Publication Date
BRPI0909840A2 true BRPI0909840A2 (pt) 2015-07-28

Family

ID=41065824

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0909840-2A BRPI0909840A2 (pt) 2008-03-12 2009-03-12 Uso de 4-tio-2-deoxinucleosídios

Country Status (12)

Country Link
US (1) US8859589B2 (pt)
EP (1) EP2262365B1 (pt)
JP (1) JP5543930B2 (pt)
KR (1) KR20100132503A (pt)
CN (1) CN101959407A (pt)
AU (1) AU2009223064B8 (pt)
BR (1) BRPI0909840A2 (pt)
CA (1) CA2718175C (pt)
EA (1) EA017705B1 (pt)
MX (1) MX2010010082A (pt)
NZ (1) NZ587915A (pt)
WO (1) WO2009114651A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI637963B (zh) 2012-03-28 2018-10-11 富士軟片股份有限公司 １－（２－脫氧－２－氟－４－硫－β－Ｄ－阿拉伯呋喃糖基）胞嘧啶之鹽
RS58568B1 (sr) 2012-08-13 2019-05-31 Fujifilm Corp Intermedijer za sintezu 1-(2-deoksi-2-fluoro-4-tio-beta-d-arabinofuranozil) citozina, intermedijer za sintezu tionukleozida, i metode za proizvodnju ovih intermedijera
JP6175553B2 (ja) * 2014-02-18 2017-08-09 富士フイルム株式会社 チオラン骨格型糖化合物の製造方法およびチオラン骨格型糖化合物
JP6204223B2 (ja) 2014-02-19 2017-09-27 富士フイルム株式会社 チオピラノース化合物等の製造方法
TWI678373B (zh) 2014-10-31 2019-12-01 日商富士軟片股份有限公司 硫代核苷衍生物或其鹽及醫藥組合物
KR102198656B1 (ko) 2016-08-31 2021-01-05 후지필름 가부시키가이샤 항종양제, 항종양 효과 증강제 및 항종양용 키트
TW201932119A (zh) 2018-01-29 2019-08-16 日商富士軟片股份有限公司 膽道癌用抗腫瘤劑和膽道癌的處理方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591722A (en) * 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
IE74701B1 (en) 1989-10-04 1997-07-30 Univ Birmingham Further antiviral pyrimidine nucleosides
US5521163A (en) * 1990-07-13 1996-05-28 University Of Birmingham Antiviral pyrimidine nucleosides and methods for using same
US20050053626A1 (en) * 2003-09-05 2005-03-10 Harrington John Ames Grace process biotechnology patent the cure to the herpes virus
JP2008538354A (ja) 2005-04-08 2008-10-23 キメリクス，インコーポレイテッド ウイルス感染症およびその他の内科疾患を治療するための化合物、組成物および方法

Also Published As

Publication number Publication date
JP2011526242A (ja) 2011-10-06
CN101959407A (zh) 2011-01-26
WO2009114651A2 (en) 2009-09-17
KR20100132503A (ko) 2010-12-17
CA2718175C (en) 2016-06-28
WO2009114651A3 (en) 2010-03-18
NZ587915A (en) 2012-02-24
CA2718175A1 (en) 2009-09-17
AU2009223064A1 (en) 2009-09-17
EP2262365A2 (en) 2010-12-22
EP2262365A4 (en) 2011-06-29
MX2010010082A (es) 2011-06-01
AU2009223064B8 (en) 2014-01-16
US20120136017A1 (en) 2012-05-31
EA201070887A1 (ru) 2011-06-30
WO2009114651A8 (en) 2009-12-03
EP2262365B1 (en) 2016-11-16
AU2009223064B2 (en) 2013-08-29
EA017705B1 (ru) 2013-02-28
JP5543930B2 (ja) 2014-07-09
US8859589B2 (en) 2014-10-14

Similar Documents

Publication Publication Date Title
BRPI1012533A2 (pt) composto de piradazinona e uso do mesmo
BRPI0906186A2 (pt) composto e uso de um composto
BRPI0821668A2 (pt) Uso
BRPI0917535A2 (pt) uso de insulina de ação ultra rápida
SMT201500218B (it) Composti aril-fenil-solfonammido-cicloalchile e loro uso
BRPI0921327A2 (pt) Combinação de herbicida-protetor
BRPI0922730A2 (pt) formulação de anticorpo
PT3812360T (pt) Compostos de monoclorotrifluoropropeno e composições e métodos utilizando os mesmos
BRPI0912213A2 (pt) preparação cosmética
EP2381760A4 (en) CORN PROTEIN COMPOSITION
HRP20180718T1 (hr) Oligopeptidni spojevi i njihova upotreba
EP2124523A4 (en) BREEDING LINE P2428-5006090
BRPI0823082A2 (pt) Uso derivados de sesquiterpeno
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
BRPI1007494A2 (pt) composto e uso do mesmo
BRPI0915086A2 (pt) detecção do uso de canabis
BRPI0915064A2 (pt) derivados de qunoxalinadiona
BRPI0915134A2 (pt) composto, e, uso de um composto
FIC20240018I1 (fi) Vamoroloni
BRPI0913832A2 (pt) derivados de pirrolopiridinilpirimidin-2-ilamina
BRPI1012728A2 (pt) uso de tripeptídeos
BRPI0913833A2 (pt) uso de corantes ácidos
BRPI0913234A2 (pt) derivados de tiazolilpiperidina
BRPI1011036A2 (pt) uso
BRPI0922652A2 (pt) Derivados de quinazolinamida

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 11A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2557 DE 07/01/2020.